Therapix Biosciences Ltd (TRPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapixs major product candidates include THX-110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-150, for the treatment of infectious diseases; and THX-160, for the treatment of treat pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapix Biosciences is headquartered in Tel Aviv, Israel.

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Therapix Biosciences Enters into Agreement with Dalhousie University 12
CURE Pharma Enters into Agreement with Therapix Biosciences 13
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 14
Therapix Biosciences Enters into Agreement with Assuta Medical Center 15
Therapix Biosciences Enters into Agreement with Catalent 16
CURE Pharmaceutical and Therapix Biosciences to Enter into Research Agreement with Assuta Medical Centers 17
Therapix Biosciences Plans to Form Joint Venture in China 18
Acebright To Enter Into Co-Development Agreement With NasVax 19
Licensing Agreements 20
Therapix Biosciences Enters into Licensing Agreement with Belvit Pharma 20
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 21
Therapix Biosciences to Enter into Licensing Agreement with Swiss Pharma Company 22
Therapix Biosciences Enters into Licensing Agreement with Ramot at Tel Aviv University 23
Therapix Biosciences Enters into Licensing Agreement with Dekel Pharma 24
Therapix Biosciences Enters into Licensing Agreement with Nanjing BioSciKin for Anti-CD3 25
Equity Offering 26
Therapix Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of ADSs for USD13.8 Million 26
Therapix Biosciences Raises USD1 Million in Private Placement of Shares 28
Therapix Biosciences Raises USD0.8 Million in Private Placement of Shares 29
Therapix Biosciences Raises USD0.6 Million in Private Placement of Shares 30
Therapix Biosciences Raises USD0.1 Million in Private Placement of Shares 31
Therapix Biosciences Raises USD0.2 Million in Private Placement of Shares 32
Therapix Biosciences Raises USD1 Million in Public Offering of Shares 33
Asset Transactions 34
CURE Pharma Plans to Acquire Assets from Therapix Biosciences 34
Acquisition 35
FSD Pharma to Acquire Therapix Biosciences 35
Therapix Biosciences to Acquire Dekel Pharma 37
Therapix Biosciences Acquires 48.21% Stake in Lara Pharm 38
Acebright To Acquire 10% Stake In NasVax For US$1 Million 39
Therapix Biosciences Ltd - Key Competitors 40
Therapix Biosciences Ltd - Key Employees 41
Therapix Biosciences Ltd - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 20, 2018: Therapix Biosciences reports second quarter 2018 financial results and provides business update 43
May 31, 2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 45
Nov 09, 2017: Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update 47
Aug 10, 2017: Therapix Biosciences Reports Second Quarter 2017 Financial Results and Provides Business Update 48
Corporate Communications 49
Jun 27, 2018: Therapix Biosciences Updates Regarding TASE Delisting 49
May 09, 2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange 50
Nov 02, 2017: Therapix Biosciences Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer 51
May 24, 2017: Therapix Biosciences Announces CEO Change 52
May 03, 2017: Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer 53
Product Approvals 54
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected 54
Clinical Trials 55
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome 55
Jun 05, 2018: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug 56
Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program 57
Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain 58
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program 59
Sep 27, 2017: Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study 60
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome 61
Jan 04, 2017: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourettes Syndrome Using Cannabinoid-based Drug 62
Other Significant Developments 63
May 15, 2018: Therapix Biosciences Issues CEOs Letter to Shareholders 63
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List Of Tables


Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Enters into Agreement with Dalhousie University 12
CURE Pharma Enters into Agreement with Therapix Biosciences 13
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 14
Therapix Biosciences Enters into Agreement with Assuta Medical Center 15
Therapix Biosciences Enters into Agreement with Catalent 16
CURE Pharmaceutical and Therapix Biosciences to Enter into Research Agreement with Assuta Medical Centers 17
Therapix Biosciences Plans to Form Joint Venture in China 18
Acebright To Enter Into Co-Development Agreement With NasVax 19
Therapix Biosciences Enters into Licensing Agreement with Belvit Pharma 20
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 21
Therapix Biosciences to Enter into Licensing Agreement with Swiss Pharma Company 22
Therapix Biosciences Enters into Licensing Agreement with Ramot at Tel Aviv University 23
Therapix Biosciences Enters into Licensing Agreement with Dekel Pharma 24
Therapix Biosciences Enters into Licensing Agreement with Nanjing BioSciKin for Anti-CD3 25
Therapix Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of ADSs for USD13.8 Million 26
Therapix Biosciences Raises USD1 Million in Private Placement of Shares 28
Therapix Biosciences Raises USD0.8 Million in Private Placement of Shares 29
Therapix Biosciences Raises USD0.6 Million in Private Placement of Shares 30
Therapix Biosciences Raises USD0.1 Million in Private Placement of Shares 31
Therapix Biosciences Raises USD0.2 Million in Private Placement of Shares 32
Therapix Biosciences Raises USD1 Million in Public Offering of Shares 33
CURE Pharma Plans to Acquire Assets from Therapix Biosciences 34
FSD Pharma to Acquire Therapix Biosciences 35
Therapix Biosciences to Acquire Dekel Pharma 37
Therapix Biosciences Acquires 48.21% Stake in Lara Pharm 38
Acebright To Acquire 10% Stake In NasVax For US$1 Million 39
Therapix Biosciences Ltd, Key Competitors 40
Therapix Biosciences Ltd, Key Employees 41
Therapix Biosciences Ltd, Subsidiaries 42

List Of Figures


Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders.

USD 250 View Report

Therapix Biosciences Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Therapix Biosciences Ltd Company Profile is a detailed strategic and analytical report on Therapix Biosciences Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders.

USD 250 View Report

Inflection Biosciences Ltd - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Inflection Biosciences Ltd (Inflection Biosciences) is a drug development company focused on discovery and development of small molecule therapeutics for the treatment of cancer. The companys pipeline products include dual

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available